Hämatologie 2009

Was ist neu?

• Antikoagulation: Statine vermindern Risiko für Beinvenenthrombosen.

• Idiopathische thrombozytopenische Purpura: Eltrombopag und Romiplostim erhöhen Thrombozytenzahl bei chronischer refraktärer ITP.

• Hämatologische Diagnostik: Neue WHO-Klassifikation für die Diagnose und Klassifikation hämatologischer Neoplasien.

• Akute myelosiche Leukämie: Sehr ungünstige Prognose bei monosomalem Karyotyp.

• Multiples Myelom: Neue Möglichkeiten bei älteren Patienten mit der „targeted therapy”.

• Follikuläres Lymphom:Rituximab-Erhaltung und autologe Transplantation verbessern Gesamtüberleben beim Rezidiv.

• Aggressive Lymphome: Strahlentherapie nur bei Restlymphomen nach Chemotherapie.

• Chronische lymphatische Leukämie:Rituximab+Chemotherapie Therapiestandard.

Literatur

• 1 Breems D A, Van Putten W L, De Greef G E. et al . Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.  J Clin Oncol. 2008;  26 4791-4797
• 2 Bussel J B, Cheng G, Saleh M N. et al . Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.  N Engl J Med. 2007;  357 2237-2247
• 3 Glynn R J, Danielson E, Fonseca R AH. et al . A randomized trial of rosuvastatin in the prevention of venous thromboembolism.  N Engl J Med. 2009;  360 1851-1861
• 4 Hallek M, Fingerle-Rowson G, Fink A -M. et al . Immunochemotherapy with Fludarabine (F), Cyclophosphamid and Rituximab (R) (FCR) versus Fludarabine and Cyclophosphamid (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL).  Blood. 2008;  112 , Abstract 325
• 5 Hulin C, Facon T, Rodon P. et al . Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial.  J Clin Oncol. 2009 May 18. [Epub ahead of print]; 
• 6 Kuter D J, Bussel J B, Lyons R M. et al . Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.  Lancet. 2008;  371 395-403
• 7 Palumbo A, Bringhen S, Liberati A M. et al . Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.  Blood. 2008;  112 3107-3114
• 8 Pfreundschuh M, Ziepert M, Reiser M. et al . The role of radiotherapy to bulky disease in the Rituximab Era: results from two prospective trials of the German high grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for elderly patients with DLBCL.  Blood. 2008;  112 , Abstract 584
• 9 San M iguel JF, Schlag R, Khuageva N. et al, K VISTA Trial Investigators . Bortezomib plus melphalane and prednisone for initial treatment of multiple myeloma.  N Engl J Med. 2008;  359 906-917
• 10 Sebban C, Brice P, Delarue R. et al . Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study.  J Clin Oncol. 2008;  26 3614-3620
• 11 Swerdlow S H, Campo E, Harris N L. et al .WHO classification of Tumours of the Haematopoietic and Lymphoid Tissues. Geneva, Switzerland; WHO press 2008
• 12 Vidal L, Gafter-Gvili A, Leibovici L. et al . Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials.  J Natl Cancer Inst. 2009;  101 248-255
• 13 Weigert O, Uysal A, Metzner B. et al . Impact of Autologous Stem Cell Transplantation and/or Rituximab on Outcome of Patients with Relapsed Follicular Lymphoma – Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG).  Blood. 2008;  112 , Abstract 2189